Drug updated on 12/11/2024
| Dosage Form | Capsule (oral; 150 mg) |
| Drug Class | Azole antifungals |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Oteseconazole significantly reduced the incidence of recurrent vulvovaginal candidiasis (RVVC) through week 48, with an odds ratio (OR) of 0.07 (95% confidence interval (CI): 0.05–0.11, p < 0.00001).
- The incidence of RVVC was also significantly reduced by Oteseconazole through week 24, with an OR of 0.05 (95% CI: 0.03–0.09, p < 0.00001).
- No specific population or subgroup findings were provided regarding differences in effectiveness.
- Oteseconazole was non-significantly associated with developing serious adverse effects compared to placebo, with an OR of 0.79 (95% CI: 0.33-1.89, p=0.60).
- There were no significant safety concerns or adverse effects identified for Oteseconazole in the reviewed documents.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vivjoa (oteseconazole) Prescribing Information. | 2024 | Mycovia Pharmaceuticals, Inc., Durham, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| "Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis" | 2023 | Heliyon |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods. | 2023 | Journal of Clinical Medicine |